Exicure Inc. (XCUR) - Price to Earnings Ratio

Corporate emblem and logo of Exicure Corp (XCUR)

The price history of Exicure, Inc. (XCUR) with the -0.80 metric demonstrates business development where nucleic acid synthesis is automated using high-precision robots. Process efficiency is further enhanced by the rapid air delivery of small reagent batches without delays. The foundation of success lies in large-scale R&D investments, which have enabled Exicure, Inc. (XCUR) to become a leader in creating spherical nucleic acid-based drugs for genome editing.

exicuretx.com (XCUR): Price to Earnings Ratio from 07/04/2022 to 11/12/2026

Analytical breakdowns for Exicure Inc. (XCUR)

- market value and analyst target forecast:
Market Chart Exicure Corp|XCUR - Analyst Consensus Forecast
- market capitalization indicators:
Market Valuation Exicure, Inc.|XCUR - Real Price to Acquire Entire Company
- balance sheet equity data:
Book Value per Share Exicure|XCUR - Company Book Value|Market Value to Book Value exicuretx.com|XCUR - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Exicure, Inc.|XCUR - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Exicure Corp|XCUR - Company Aggregate Debts|Debts to Net Assets Exicure, Inc.|XCUR - Company Long-Term Debt|Company Short-Term Indebtedness Exicure|Quick Liquidity Indicator exicuretx.com
- net income and valuation ratios data:
XCUR - Net Income|Company Profit Forecast Exicure, Inc.|XCUR - Price to Earnings Ratio|Price to Future Earnings Ratio Exicure Corp|XCUR - PEG Multiple|Enterprise Value to EBITDA Ratio Exicure, Inc.|XCUR - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Exicure|XCUR - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months exicuretx.com|XCUR - Earnings growth in current year|Projected earnings per share growth rate for next year Exicure, Inc.
Summary company analysis:Exicure, Inc.
Original product of Exicure, Inc.

Assessing the financial stability of Exicure, Inc. (XCUR) requires an analysis of the market capitalization to net income ratio, which helps identify whether the asset is overpriced or faces low liquidity risks. By examining the company's price-to-earnings trend, an investor can see how an ultra-compact staffing structure and reliance on external contracts impact the speed of institutional capital exits without triggering a price collapse.

Analysis of competing companies

Tempus AI Inc (TEM) - Business Payback Period|P/E Multiple QGEN|Price to Earnings Ratio Ionis Pharmaceuticals, Inc. IONS|Repligen Corp. - Price to Earnings Ratio|P/E Multiple Avidity Corp RNA|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (genedx.com)|RARE: P/E Multiple|Market Cap to Earnings Beam Therapeutics Inc (BEAM)|Price to Earnings Ratio SRPT|TWST: Company Value to Net Income|P/E Multiple TXG|Business Payback Period intelliatx.com|Price to Earnings Ratio Stoke Therapeutics, Inc. STOK|BLFS: Price to Earnings Multiple|Wave Life Sciences Corp - P/E Multiple|Maze Therapeutics Corp (MAZE) - Price to Earnings Ratio|SION (Sionna Therapeutics Inc) - Price to Earnings Ratio|PRME - Business Payback Period|Price to Earnings Ratio TSHA|Price to Earnings Multiple QURE (uniQure NV)|P/E Multiple MGTX|Price to Earnings Ratio REGENXBIO Corp RGNX|Solid Biosciences Inc. - Price to Earnings Ratio|P/E Multiple ocugen.com OCGN|PACB - Price to Earnings Ratio|Company Value to Net Income BNTC (Benitec Biopharma Inc)|DSGN: P/E Multiple|Price to Earnings Multiple RCKT|Price to Earnings Ratio 4D Molecular Therapeutics|Price to Earnings Multiple LXEO (Lexeo)|P/E Multiple KRRO|P/E Multiple Editas Medicine Inc (EDIT)|P/E Multiple SLN (Silence Therapeutics Inc.)|ProQR (PRQR) - Market Cap to Earnings|CDXS: Price to Earnings Ratio|SGMO (sangamo.com) - Price to Earnings Multiple|NAUT: P/E Multiple|MGX - Business Payback Period|DTIL (Precision BioSciences, Inc.) - P/E Multiple|Price to Earnings Ratio Generation Bio Corp (GBIO)|Price to Earnings Ratio BOLD (Boundless Bio, Inc.)|P/E Multiple imunon.com (IMNN)|Price to Earnings Ratio Phio Pharmaceuticals Corp. PHIO|Company Value to Net Income MBIO|TransCode - P/E Multiple|Market Cap to Earnings Bionano Genomics, Inc.|APDN (Applied DNA Sciences) - Price to Earnings Ratio|bluebirdbio.com - Company Value to Net Income|IPA (ImmunoPrecise Antibodies Ltd) - P/E Multiple|Omega Therapeutics Inc (OMGA) - Business Payback Period|Price to Earnings Ratio Singular Genomics Systems Inc (OMIC)|Regulus - Price to Earnings Multiple|P/E Multiple SYRS (Syros Pharmaceuticals)|TBIO - Price to Earnings Ratio|TCON: Price to Earnings Ratio|Business Payback Period Unity Biotechnology Inc. UBX